search
Back to results

A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI Score (MECKI)

Primary Purpose

HF - Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
CPET and related variables evaluation
Sponsored by
Centro Cardiologico Monzino
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HF - Heart Failure focused on measuring Cardiopulmonary exercise testing- CPET, Metabolic Exercise Cardiac Kidney Indexes (MECKI) score

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Previous or present HF symptoms (NYHA functional class I-IV, stage B and C of ACC/AHA classification) history or presence of left ventricular ejection fraction (LVEF)<40% unchanged HF medications for at least three months ability to perform a CPET no major cardiovascular treatment or intervention scheduled Exclusion Criteria: History of pulmonary embolism moderate-to-severe aortic and mitral stenosis pericardial disease severe obstructive lung disease exercise-induced angina significant ECG alterations, or presence of any clinical comorbidity interfering with exercise performance

Sites / Locations

  • IRCCS Centro Cardiologico MonzinoRecruiting
  • Università di Napoli Federico IIRecruiting
  • Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
  • Fondazione Toscana Gabriele Monasterio per la ricerca medica e di sanità pubblicaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sigle arm study

Arm Description

HF patients who meets all the inclusion and none of the exclusion criteria

Outcomes

Primary Outcome Measures

Day-by-day variability of MECKI score
Day by day variability of MECKI score will be done by comparing MECKI score value obtained at study run-in (day 0) and in a second evaluation of MECKI score performed within 2 weeks.
Identification of interobserver variability
CPET interobservers variability will be done by assessing CPET analysis done by two recognized CPET experts blinded on patients data

Secondary Outcome Measures

Time-related dynamic changes of peak oxygen intake (VO2)
Modifications in peak oxygen intake (VO2) in 6-12-18-24 months will be evaluated in relation to prognosis
Time-related dynamic changes of minute ventilation/carbon dioxide production (VE/VCO2) slope
Modifications in minute ventilation/carbon dioxide production (VE/VCO2) slope in 6-12-18-24 months will be evaluated in relation to prognosis
Time-related dynamic changes of MDRD
Modifications of MDRD in 6-12-18-24 months will be evaluated in relation to prognosis
Time-related dynamic changes of LVEF
Modifications of LVEF in 6-12-18-24 months will be evaluated in relation to prognosis
Time-related dynamic changes of hemoglobin
Modifications of hemoglobin in 6-12-18-24 months will be evaluated in relation to prognosis
Time-related dynamic changes of Na+
Modifications of Na+ in 6-12-18-24 months will be evaluated in relation to prognosis
The identification of the prognostic meaning of MECKI score changes at 6 months
Modifications of MECKI score at 6 months will be evaluated in relation to prognosis
The identification of the prognostic meaning of MECKI score changes at one year
Modifications of MECKI score at one year will be evaluated in relation to prognosis

Full Information

First Posted
October 2, 2023
Last Updated
October 2, 2023
Sponsor
Centro Cardiologico Monzino
Collaborators
Federico II University, Fondazione Toscana Gabriele Monasterio, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
search

1. Study Identification

Unique Protocol Identification Number
NCT06070519
Brief Title
A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI Score
Acronym
MECKI
Official Title
A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI Score
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centro Cardiologico Monzino
Collaborators
Federico II University, Fondazione Toscana Gabriele Monasterio, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The project is dedicated to the improvement of our capability to provide a precise and personalized prognosis in heart failure (HF) patients in stable conditions. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score is one of the 3 HF prognostic models recommended by the 2021 European HF guidelines and it is considered the most powerful prognostic tool available. MECKI score integrates cardiopulmonary exercise test (CPET) data with easy-to-obtain clinical, laboratory, and echocardiographic variables. It is based on 6 parameters: peak oxygen intake (peakVO2), minute ventilation/carbon dioxide production (VE/VCO2 slope), hemoglobin (Hb), Left Ventricle Ejection Fraction (LVEF), kidney function by Modification of Diet in Renal Disease (MDRD) formula, and sodium (Na+). The aim of the present project is to assess the day-by-day MECKI score variability, CPET parameters interobserver variability, characterization of HF patients who change MECKI score values in 6 and 12 months, and the prognostic meaning of time dependent MECKI score changes.
Detailed Description
This is a low-intervention multicenter clinical trial aim at evaluating the role of time dependent prognostic parameters changes, moving from the single shot evaluation to dynamic analysis. Each participant center will perform patients' recruitment and follow up. At the baseline visit, CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, study procedures aimed to calculate MECKI score will be performed: Echocardiography (Left Ventricle Ejection Fraction - LVEF) Blood sample (Na+, MDRD, Hb) Maximal ramp protocol CPET (peakVO2, minute ventilation/carbon dioxide production (VE/VCO2) slope - VE/VCO2 slope)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HF - Heart Failure
Keywords
Cardiopulmonary exercise testing- CPET, Metabolic Exercise Cardiac Kidney Indexes (MECKI) score

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sigle arm study
Arm Type
Experimental
Arm Description
HF patients who meets all the inclusion and none of the exclusion criteria
Intervention Type
Diagnostic Test
Intervention Name(s)
CPET and related variables evaluation
Intervention Description
At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed: Echocardiography (LVEF) Blood sample (Na+, MDRD, Hb) Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)
Primary Outcome Measure Information:
Title
Day-by-day variability of MECKI score
Description
Day by day variability of MECKI score will be done by comparing MECKI score value obtained at study run-in (day 0) and in a second evaluation of MECKI score performed within 2 weeks.
Time Frame
through study completion, an average of 3 year
Title
Identification of interobserver variability
Description
CPET interobservers variability will be done by assessing CPET analysis done by two recognized CPET experts blinded on patients data
Time Frame
through study completion, an average of 3 year
Secondary Outcome Measure Information:
Title
Time-related dynamic changes of peak oxygen intake (VO2)
Description
Modifications in peak oxygen intake (VO2) in 6-12-18-24 months will be evaluated in relation to prognosis
Time Frame
through study completion, an average of 3 year
Title
Time-related dynamic changes of minute ventilation/carbon dioxide production (VE/VCO2) slope
Description
Modifications in minute ventilation/carbon dioxide production (VE/VCO2) slope in 6-12-18-24 months will be evaluated in relation to prognosis
Time Frame
through study completion, an average of 3 year
Title
Time-related dynamic changes of MDRD
Description
Modifications of MDRD in 6-12-18-24 months will be evaluated in relation to prognosis
Time Frame
through study completion, an average of 3 year
Title
Time-related dynamic changes of LVEF
Description
Modifications of LVEF in 6-12-18-24 months will be evaluated in relation to prognosis
Time Frame
through study completion, an average of 3 year
Title
Time-related dynamic changes of hemoglobin
Description
Modifications of hemoglobin in 6-12-18-24 months will be evaluated in relation to prognosis
Time Frame
through study completion, an average of 3 year
Title
Time-related dynamic changes of Na+
Description
Modifications of Na+ in 6-12-18-24 months will be evaluated in relation to prognosis
Time Frame
through study completion, an average of 3 year
Title
The identification of the prognostic meaning of MECKI score changes at 6 months
Description
Modifications of MECKI score at 6 months will be evaluated in relation to prognosis
Time Frame
6 months
Title
The identification of the prognostic meaning of MECKI score changes at one year
Description
Modifications of MECKI score at one year will be evaluated in relation to prognosis
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Previous or present HF symptoms (NYHA functional class I-IV, stage B and C of ACC/AHA classification) history or presence of left ventricular ejection fraction (LVEF)<40% unchanged HF medications for at least three months ability to perform a CPET no major cardiovascular treatment or intervention scheduled Exclusion Criteria: History of pulmonary embolism moderate-to-severe aortic and mitral stenosis pericardial disease severe obstructive lung disease exercise-induced angina significant ECG alterations, or presence of any clinical comorbidity interfering with exercise performance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Piergiuseppe Agostoni, Prof
Phone
02 58002586
Email
piergiuseppe.agostoni@cardiologicomonzino.it
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabetta Salvioni, PhD
Phone
0258002010
Email
elisabetta.salvioni@cardiologicomonzino.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Piergiuseppe Agostoni, Prof
Organizational Affiliation
IRCCS Centro Cardiologico Monzino
Official's Role
Principal Investigator
Facility Information:
Facility Name
IRCCS Centro Cardiologico Monzino
City
Milano
State/Province
Milan
ZIP/Postal Code
20138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Piergiuseppe Agostoni, Prof
Phone
02 58002586
Email
piergiuseppe.agostoni@cardiologicomonzino.it
First Name & Middle Initial & Last Name & Degree
Elisabetta Salvioni, PhD
Phone
02 58002010
Email
elisabetta.salvioni@cardiologicomonzino.it
Facility Name
Università di Napoli Federico II
City
Napoli
ZIP/Postal Code
80138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefania Paolillo, Prof
Email
paolilloste@gmail.com
Facility Name
Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
City
Palermo
ZIP/Postal Code
90127
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manlio Cipriani, MD
Email
mcipriani@ismett.edu
Facility Name
Fondazione Toscana Gabriele Monasterio per la ricerca medica e di sanità pubblica
City
Pisa
ZIP/Postal Code
56124
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Emdin, Prof
Email
m.emdin@santannapisa.it

12. IPD Sharing Statement

Citations:
PubMed Identifier
34447992
Citation
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available. Erratum In: Eur Heart J. 2021 Oct 14;:
Results Reference
background
PubMed Identifier
22795401
Citation
Agostoni P, Corra U, Cattadori G, Veglia F, La Gioia R, Scardovi AB, Emdin M, Metra M, Sinagra G, Limongelli G, Raimondo R, Re F, Guazzi M, Belardinelli R, Parati G, Magri D, Fiorentini C, Mezzani A, Salvioni E, Scrutinio D, Ricci R, Bettari L, Di Lenarda A, Pastormerlo LE, Pacileo G, Vaninetti R, Apostolo A, Iorio A, Paolillo S, Palermo P, Contini M, Confalonieri M, Giannuzzi P, Passantino A, Cas LD, Piepoli MF, Passino C; MECKI Score Research Group. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. Int J Cardiol. 2013 Sep 10;167(6):2710-8. doi: 10.1016/j.ijcard.2012.06.113. Epub 2012 Jul 15.
Results Reference
background
PubMed Identifier
28949086
Citation
Agostoni P, Paolillo S, Mapelli M, Gentile P, Salvioni E, Veglia F, Bonomi A, Corra U, Lagioia R, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Metra M, Carubelli V, Scrutinio D, Raimondo R, Emdin M, Piepoli M, Magri D, Parati G, Caravita S, Re F, Cicoira M, Mina C, Correale M, Frigerio M, Bussotti M, Oliva F, Battaia E, Belardinelli R, Mezzani A, Pastormerlo L, Guazzi M, Badagliacca R, Di Lenarda A, Passino C, Sciomer S, Zambon E, Pacileo G, Ricci R, Apostolo A, Palermo P, Contini M, Clemenza F, Marchese G, Gargiulo P, Binno S, Lombardi C, Passantino A, Filardi PP. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur J Heart Fail. 2018 Apr;20(4):700-710. doi: 10.1002/ejhf.989. Epub 2017 Sep 26.
Results Reference
background
PubMed Identifier
30632680
Citation
Paolillo S, Veglia F, Salvioni E, Corra U, Piepoli M, Lagioia R, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Metra M, Senni M, Bonomi A, Scrutinio D, Raimondo R, Emdin M, Magri D, Parati G, Re F, Cicoira M, Mina C, Correale M, Frigerio M, Bussotti M, Battaia E, Guazzi M, Badagliacca R, Di Lenarda A, Maggioni A, Passino C, Sciomer S, Pacileo G, Mapelli M, Vignati C, Clemenza F, Binno S, Lombardi C, Filardi PP, Agostoni P; MECKI Score Research Group (see Appendix). Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. Eur J Heart Fail. 2019 Feb;21(2):208-217. doi: 10.1002/ejhf.1364. Epub 2019 Jan 11.
Results Reference
background
PubMed Identifier
33238744
Citation
Salvioni E, Bonomi A, Re F, Mapelli M, Mattavelli I, Vitale G, Sarullo FM, Palermo P, Veglia F, Agostoni P. The MECKI score initiative: Development and state of the art. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):5-11. doi: 10.1177/2047487320959010.
Results Reference
background

Learn more about this trial

A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI Score

We'll reach out to this number within 24 hrs